Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Nanocarrier-based systems for targeted and site specific therapeutic delivery.

Majumder J, Taratula O, Minko T.

Adv Drug Deliv Rev. 2019 Apr;144:57-77. doi: 10.1016/j.addr.2019.07.010. Epub 2019 Aug 7. Review.

PMID:
31400350
2.

Prevention of paclitaxel-induced neuropathy by formulation approach.

Zang X, Lee JB, Deshpande K, Garbuzenko OB, Minko T, Kagan L.

J Control Release. 2019 Jun 10;303:109-116. doi: 10.1016/j.jconrel.2019.04.013. Epub 2019 Apr 11.

PMID:
30981814
3.

Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers.

Garbuzenko OB, Kbah N, Kuzmov A, Pogrebnyak N, Pozharov V, Minko T.

J Control Release. 2019 Feb 28;296:225-231. doi: 10.1016/j.jconrel.2019.01.025. Epub 2019 Jan 21.

4.

On the plasticizing properties of divalproex sodium: physicochemical and spectroscopic characterization studies.

Khatri P, Desai D, Minko T.

Pharm Dev Technol. 2019 Apr;24(4):455-464. doi: 10.1080/10837450.2018.1514049. Epub 2018 Nov 6.

PMID:
30396305
5.

Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer.

Shaik T, Rather GM, Bansal N, Minko T, Garbuzenko O, Szekely Z, Abali EE, Banerjee D, Kerrigan JE, Scotto KW, Bertino JR.

Oncotarget. 2018 Sep 7;9(70):33249-33257. doi: 10.18632/oncotarget.26064. eCollection 2018 Sep 7.

6.

Metastatic and triple-negative breast cancer: challenges and treatment options.

Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T.

Drug Deliv Transl Res. 2018 Oct;8(5):1483-1507. doi: 10.1007/s13346-018-0551-3. Review.

7.

Molecular imaging for precision medicine.

Lu ZR, Minko T.

Adv Drug Deliv Rev. 2017 Apr;113:1-2. doi: 10.1016/j.addr.2017.08.002. No abstract available.

PMID:
28821310
8.

Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s).

Garbuzenko OB, Ivanova V, Kholodovych V, Reimer DC, Reuhl KR, Yurkow E, Adler D, Minko T.

Nanomedicine. 2017 Aug;13(6):1983-1992. doi: 10.1016/j.nano.2017.04.005. Epub 2017 Apr 19.

9.

Precision targeted therapy of ovarian cancer.

Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T.

J Control Release. 2016 Dec 10;243:250-268. doi: 10.1016/j.jconrel.2016.10.014. Epub 2016 Oct 14. Review.

10.

LHRH-Targeted Drug Delivery Systems for Cancer Therapy.

Li X, Taratula O, Taratula O, Schumann C, Minko T.

Mini Rev Med Chem. 2017;17(3):258-267. Review.

11.

Nanoparticle design considerations for molecular imaging of apoptosis: Diagnostic, prognostic, and therapeutic value.

Savla R, Minko T.

Adv Drug Deliv Rev. 2017 Apr;113:122-140. doi: 10.1016/j.addr.2016.06.016. Epub 2016 Jun 29. Review.

PMID:
27374457
12.

Development of edge-activated liposomes for siRNA delivery to human basal epidermis for melanoma therapy.

Dorrani M, Garbuzenko OB, Minko T, Michniak-Kohn B.

J Control Release. 2016 Apr 28;228:150-158. doi: 10.1016/j.jconrel.2016.03.010. Epub 2016 Mar 8.

PMID:
26965957
13.

Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer.

Yin PT, Shah S, Pasquale NJ, Garbuzenko OB, Minko T, Lee KB.

Biomaterials. 2016 Mar;81:46-57. doi: 10.1016/j.biomaterials.2015.11.023. Epub 2015 Nov 12.

14.

Nanotechnology approaches for inhalation treatment of lung diseases.

Kuzmov A, Minko T.

J Control Release. 2015 Dec 10;219:500-518. doi: 10.1016/j.jconrel.2015.07.024. Epub 2015 Aug 19. Review.

16.

Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs.

Garbuzenko OB, Winkler J, Tomassone MS, Minko T.

Langmuir. 2014 Nov 4;30(43):12941-9. doi: 10.1021/la502144z. Epub 2014 Oct 27.

17.

Delivery of antisense oligonucleotides using poly(alkylene oxide)-poly(propylacrylic acid) graft copolymers in conjunction with cationic liposomes.

Peddada LY, Garbuzenko OB, Devore DI, Minko T, Roth CM.

J Control Release. 2014 Nov 28;194:103-12. doi: 10.1016/j.jconrel.2014.08.023. Epub 2014 Sep 1.

18.

Dendritic silica nanomaterials (KCC-1) with fibrous pore structure possess high DNA adsorption capacity and effectively deliver genes in vitro.

Huang X, Tao Z, Praskavich JC Jr, Goswami A, Al-Sharab JF, Minko T, Polshettiwar V, Asefa T.

Langmuir. 2014 Sep 16;30(36):10886-98. doi: 10.1021/la501435a. Epub 2014 Sep 4.

PMID:
25188675
19.

Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy.

Savla R, Garbuzenko OB, Chen S, Rodriguez-Rodriguez L, Minko T.

Pharm Res. 2014 Dec;31(12):3487-502. doi: 10.1007/s11095-014-1436-x. Epub 2014 Jun 13.

20.

Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention.

Garbuzenko OB, Mainelis G, Taratula O, Minko T.

Cancer Biol Med. 2014 Mar;11(1):44-55. doi: 10.7497/j.issn.2095-3941.2014.01.004.

21.

A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts.

Xie X, Bansal N, Shaik T, Kerrigan JE, Minko T, Garbuzenko O, Abali EE, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR.

Oncotarget. 2014 Feb 28;5(4):901-7.

22.

Nanotechnology and drug resistance.

Minko T.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1665-6. doi: 10.1016/j.addr.2013.10.005. Epub 2013 Oct 29. No abstract available.

PMID:
24177352
23.

Nanotechnology approaches for personalized treatment of multidrug resistant cancers.

Minko T, Rodriguez-Rodriguez L, Pozharov V.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1880-95. doi: 10.1016/j.addr.2013.09.017. Epub 2013 Oct 10. Review.

24.

Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.

Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T.

Clin Cancer Res. 2013 Nov 15;19(22):6193-204. doi: 10.1158/1078-0432.CCR-13-1536. Epub 2013 Sep 13.

25.

Nanotechnology approaches for inhalation treatment of fibrosis.

Savla R, Minko T.

J Drug Target. 2013 Dec;21(10):914-25. doi: 10.3109/1061186X.2013.829078. Epub 2013 Aug 27. Review.

26.

Preface-tenth international nanomedicine and drug delivery symposium (NanoDDS'12).

Minko T, Hatefi A.

J Control Release. 2013 Nov 10;171(3):259-60. doi: 10.1016/j.jconrel.2013.08.008. Epub 2013 Aug 15. No abstract available.

PMID:
23954371
27.

Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.

Xie X, Kerrigan JE, Minko T, Garbuzenko O, Lee KC, Scarborough A, Abali EE, Budak-Alpdogan T, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR.

Cancer Biol Ther. 2013 Aug;14(8):742-51. doi: 10.4161/cbt.25184. Epub 2013 Jun 3.

28.

Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.

Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T.

J Control Release. 2013 Nov 10;171(3):349-57. doi: 10.1016/j.jconrel.2013.04.018. Epub 2013 May 3.

29.

Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice.

Mainelis G, Seshadri S, Garbuzenko OB, Han T, Wang Z, Minko T.

J Aerosol Med Pulm Drug Deliv. 2013 Dec;26(6):345-54. doi: 10.1089/jamp.2011-0966. Epub 2013 Mar 26.

30.

Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

Ivanova V, Garbuzenko OB, Reuhl KR, Reimer DC, Pozharov VP, Minko T.

Eur J Pharm Biopharm. 2013 Jun;84(2):335-44. doi: 10.1016/j.ejpb.2012.11.023. Epub 2012 Dec 8.

31.

Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids.

Shah V, Taratula O, Garbuzenko OB, Patil ML, Savla R, Zhang M, Minko T.

Curr Drug Discov Technol. 2013 Mar;10(1):8-15.

32.

Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases.

Zhang M, Garbuzenko OB, Reuhl KR, Rodriguez-Rodriguez L, Minko T.

Nanomedicine (Lond). 2012 Feb;7(2):185-97. doi: 10.2217/nnm.11.131.

PMID:
22339132
33.

Advances in image-guided drug delivery.

Hatefi A, Minko T.

Drug Deliv Transl Res. 2012 Feb;2(1):1-2. doi: 10.1007/s13346-011-0057-8. No abstract available.

PMID:
25786596
34.

Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.

Sheihet L, Garbuzenko OB, Bushman J, Gounder MK, Minko T, Kohn J.

Eur J Pharm Sci. 2012 Feb 14;45(3):320-9. doi: 10.1016/j.ejps.2011.11.017. Epub 2011 Dec 3.

35.

Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer.

Nadler-Milbauer M, Apter L, Haupt Y, Haupt S, Barenholz Y, Minko T, Rubinstein A.

J Drug Target. 2011 Dec;19(10):859-73. doi: 10.3109/1061186X.2011.622401.

PMID:
22082104
36.

Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.

Taratula O, Garbuzenko OB, Chen AM, Minko T.

J Drug Target. 2011 Dec;19(10):900-14. doi: 10.3109/1061186X.2011.622404. Epub 2011 Oct 10.

PMID:
21981718
37.

Preliminary evaluation of the genotoxic potential of a hydrophilic polymer with three preservation systems.

Dayan N, Shah V, Minko T.

Int J Cosmet Sci. 2011 Dec;33(6):497-502. doi: 10.1111/j.1468-2494.2011.00661.x. Epub 2011 Jun 23.

PMID:
21696404
38.

Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage.

Betigeri S, Zhang M, Garbuzenko O, Minko T.

Drug Deliv Transl Res. 2011 Feb;1(1):13-24. doi: 10.1007/s13346-010-0003-1. Epub 2010 Dec 14.

39.

Genotoxic potential evaluation of a cosmetic insoluble substance by the micronuclei assay.

Dayan N, Shah V, Minko T.

J Cosmet Sci. 2011 Jan-Feb;62(1):29-39.

PMID:
21443843
40.

Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer.

Savla R, Taratula O, Garbuzenko O, Minko T.

J Control Release. 2011 Jul 15;153(1):16-22. doi: 10.1016/j.jconrel.2011.02.015. Epub 2011 Feb 20.

PMID:
21342659
41.

Multifunctional triblock Nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing.

Patil ML, Zhang M, Minko T.

ACS Nano. 2011 Mar 22;5(3):1877-87. doi: 10.1021/nn102711d. Epub 2011 Feb 15.

42.

Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes.

Taratula O, Garbuzenko O, Savla R, Wang YA, He H, Minko T.

Curr Drug Deliv. 2011 Jan;8(1):59-69. Review.

PMID:
21034421
43.

Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers.

Chandna P, Khandare JJ, Ber E, Rodriguez-Rodriguez L, Minko T.

Pharm Res. 2010 Nov;27(11):2296-306. doi: 10.1007/s11095-010-0235-2. Epub 2010 Aug 11.

PMID:
20700631
44.

Labile catalytic packaging of DNA/siRNA: control of gold nanoparticles "out" of DNA/siRNA complexes.

Chen AM, Taratula O, Wei D, Yen HI, Thomas T, Thomas TJ, Minko T, He H.

ACS Nano. 2010 Jul 27;4(7):3679-88. doi: 10.1021/nn901796n.

45.

Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance.

Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T.

Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10737-42. doi: 10.1073/pnas.1004604107. Epub 2010 May 24.

46.

LHRH-targeted nanoparticles for cancer therapeutics.

Minko T, Patil ML, Zhang M, Khandare JJ, Saad M, Chandna P, Taratula O.

Methods Mol Biol. 2010;624:281-94. doi: 10.1007/978-1-60761-609-2_19.

PMID:
20217603
47.

Polymer Vesicles with a Red Cell-like Surface Charge: Microvascular Imaging and in vivo Tracking with Near-Infrared Fluorescence.

Christian DA, Garbuzenko OB, Minko T, Discher DE.

Macromol Rapid Commun. 2010 Jan 18;31(2):135-41. doi: 10.1002/marc.200900589. Epub 2009 Dec 1.

PMID:
21590885
48.

HPMA copolymers for modulating cellular signaling and overcoming multidrug resistance.

Minko T.

Adv Drug Deliv Rev. 2010 Feb 17;62(2):192-202. doi: 10.1016/j.addr.2009.12.002. Epub 2009 Dec 11. Review.

PMID:
20005272
49.

Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.

Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T, He H.

Small. 2009 Dec;5(23):2673-7. doi: 10.1002/smll.200900621. No abstract available.

50.

Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery.

Taratula O, Garbuzenko OB, Kirkpatrick P, Pandya I, Savla R, Pozharov VP, He H, Minko T.

J Control Release. 2009 Dec 16;140(3):284-93. doi: 10.1016/j.jconrel.2009.06.019. Epub 2009 Jun 28.

Supplemental Content

Support Center